Skip to main content
Premium Trial:

Request an Annual Quote

GenomeWebinars

Tue
Nov
30
11:00 AM
US Eastern

Sponsored by Agena Bioscience

Pharmacogenetics-Guided Pharmacotherapy: Recent Developments and Implementation in Clinical Practice

Evidence for the impact of pharmacogenetic factors on drug effects has markedly increased in recent years. However, the inclusion of pharmacogenetics in prescription decisions in clinical practice lags behind the initial high expectations for this new field of clinical pharmacology.

This webinar will address the strengths and limitations of pharmacogenetics for modern pharmacotherapy. Stefan Russmann, clinical pharmacologist and pharmacoepidemiologist, will discuss the latest scientific evidence supporting pharmacogenetics-guided pharmacotherapy, share his first-hand experience with implementing pharmacogenetics in clinical practice, and provide an overview of how pharmacogenetics may change drug development and prescription in the future.

Russman will cover drug-drug-gene interactions, the implementation and benefits of pharmacogenetic panel testing, CYP2C19 and clopidogrel therapy, CYP2D6 and tamoxifen therapy, and DPYD and chemotherapy. In addition, the latest developments in DPYD testing from Agena Bioscience will be presented.

Sponsored by

field_file_image_alt_text_value
Wed
Dec
01
11:00 AM
US Eastern

Sponsored by Seqera Labs

Managing Bioinformatics Pipelines in the Cloud to Do More Science

In this webinar, Phil Ewels, team leader for bioinformatics development at the National Genomics Infrastructure (NGI) at SciLifeLab, Brendan Bouffler, head of developer relations, HPC Engineering at Amazon Web Services, and Evan Floden, CEO of Seqera Labs, will discuss and demonstrate how bioinformaticians and data practitioners can create, manage and optimize their data pipelines with cloud-based systems, increasing productivity, reducing the need to manage IT infrastructure, and ultimately allowing them to do more science.

Nextflow enables users to seamlessly run and scale reproducible genomics workflows locally, on high-performance computing (HPC) clusters, or on major cloud providers’ infrastructure. Developed since 2014 and backed by a fast-growing community, the Nextflow ecosystem is made up of users and developers across academia, government, and industry.

Sponsored by

Seqera Logo
Thu
Dec
02
1:00 PM
US Eastern

Sponsored by Glen Research

Precision Medicine and Rational Vaccinology Through Spherical Nucleic Acids

Spherical nucleic acids (SNAs) are typically composed of nanoparticle cores with densely functionalized and radially oriented shells composed of short (~10-30mers), synthetic nucleic acids. This novel three-dimensional architecture imparts conjugate properties that make SNAs extremely useful in biomedicine, due in part to their ability to bind complementary strands orders of magnitude more tightly than linear nucleic acids of the same sequence and their ability to enter cells in high quantities without transfection agents. SNAs are highly modular; they have been prepared with dozens of different cores, including biocompatible liposomes and proteins, and with an almost limitless variety of nucleic acid types and sequences, owing to solid-phase chemical synthesis techniques.

In the case of SNA-based vaccines, immunostimulatory oligonucleotides (adjuvants) compose the shell, with specific and even multiple types of antigens incorporated into the SNA shell or core, allowing access to a range of innate and adaptive immune responses and pathways. The discovery that the chemical structure of an SNA conjugate can transition a vaccine from mildly effective to curative has set the stage for a new field of rational vaccinology. This discovery also poses a pressing question: if a target has failed out of clinical trials previously, was it because the composition was incorrect, or was it simply delivered in the incorrect structure? Speaker Chad A. Mirkin and colleagues are answering this question in the context of devastating diseases such as cancer and COVID-19. 

In this webinar, attendees will learn how synthetic oligonucleotides:

  • Enable the restructuring of medicines on the nanoscale.
  • Permit new and usual interactions that are changing how diseases are studied, tracked, and treated.
  • Enable rapid clinical translation for the benefit of patients.

Sponsored by

field_file_image_alt_text_value
Fri
Dec
03
12:00 PM
US Eastern

Sponsored by Illumina

Library Preparation and Genome Assembly Using Transposase Enzyme-Linked Long-Read Sequencing (TELL-Seq)

In this webinar, Alvaro Hernandez, PhD, director of DNA Services at the University of Illinois at Urbana Champaign, will discuss how his team sequenced and assembled the genomes of nine insects using Transposase Enzyme-Linked Long-Read Sequencing (TELL-Seq) at different stages of genome assembly. The unique contributions of TELL-Seq libraries to the completeness of the assembly, as well as the DNA extraction, library preparation, and sequencing methods the team employed will be discussed in detail. 

The insect genomes were sequenced as a pilot project from the University of Illinois Prairie Research Institute, Carl R. Woese Institute for Genome Biology, and the Roy J. Carver Biotechnology Center to demonstrate the potential for Illinois to join a global network of communities engaged in genome assembly and the conservation of biodiversity.  

Sponsored by

field_file_image_alt_text_value
Mon
Dec
06
1:00 PM
US Eastern

Sponsored by Tecan

Whole-Genome Sequence and Electronic Health Record Machine Learning for Hospital Outbreak Detection: A Novel Paradigm

Approaches for hospital outbreak detection have remained unchanged for years. When an outbreak is suspected, a method to establish genetic relatedness such as whole-genome sequencing (WGS) may be performed. This approach can miss outbreaks and falsely identify suspected outbreaks that are refuted by WGS.

In late 2016, University of Pittsburgh Professor of Medicine and Epidemiology, Dr. Lee Harrison and colleagues began developing the Enhanced Detection System for Healthcare-Associated Transmission (EDS-HAT), which combines WGS surveillance with data mining and machine learning of the electronic health record (EHR) to detect outbreaks and correctly identify their routes of transmission, respectively. The team found EHR machine learning useful for transmission routes that cannot be identified by traditional means. The purpose of this talk is to describe the results of using this novel approach for detecting hospital outbreaks.

Participants can expect to learn:

  • The difference between reactive WGS and WGS surveillance
  • The advantages of reactive WGS and WGS surveillance
  • How data mining of the electronic health record with machine learning can be used to identify transmission routes that are not readily apparent
  • How EDS-HAT identifies outbreaks that are missed by traditional hospital infection prevention methods

Sponsored by

field_file_image_alt_text_value
Mon
Dec
06
3:00 PM
US Eastern

Sponsored by PGDx

Decentralizing Precision Oncology Trials: Opportunities and Challenges for Implementing a Patient-Centric Model

The COVID-19 pandemic restricted clinical trial operations around the world but reignited efforts among researchers and industry players to explore new tools and decentralized strategies that can bring trials closer to where patients live and receive treatment. Such approaches may be useful for the development of precision oncology drugs, especially when these therapies are for rare, biomarker-defined tumor types and require a broad biomarker testing strategy to identify the treatment-eligible population.  

Please join us on December 6th to hear four experts discuss the present challenges and opportunities in decentralizing precision cancer therapy trials: Dr. Sameek Roychowdhury, medical oncologist and member of the Translational Therapeutics Program, Ohio State University Comprehensive Cancer Center – James; Dr. Kristen Deak, associate director of clinical cytogenetics and molecular diagnostics, Duke University; Dr. Jonathan Cotliar, chief medical officer, Science 37; and Dr. Lee Schwartzberg, chief medical officer, OneOncology.  

The panelists will discuss the value of distributed and centralized comprehensive genomic profiling, liquid biopsy testing, and telemedicine in improving clinical trial participation; highlight decentralized precision oncology trials currently underway and how they differ from traditional site-based trials; reflect on effective strategies for engaging and building trust among communities typically left out of research; and discuss how to involve community oncologists in decentralized trial approaches who usually don't have the time or resources to conduct research.

Sponsored by

PGDx
Tue
Dec
07
3:00 PM
US Eastern

Sponsored by Allelica

Polygenic Risk Scores in Clinical Care: Filling the Gap in Risk Assessments for Common Diseases

Current clinical risk models rely heavily on traditional risk factors and only rarely incorporate genetic information. However, evidence that genome-wide variation contributes substantially to disease risk is mounting, with polygenic risk scores (PRS) emerging as a robust and accurate method to assess the genetic liability of disease. This webinar will explore how integrating PRS into clinical risk assessments leads to greater precision by enabling greater numbers of people at high genetic risk of disease to be identified and treated with disease-reduction interventions.

Dr. Noura Abul-Husn, clinical director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai, will provide insights on how PRS can be used to increase precision in risk assessment compared to current clinical genetic screening approaches, describe diverse patients’ perspectives on the use of clinical PRS, and discuss ongoing efforts to implement clinical PRS for common diseases in diverse populations. Professor Pradeep Natarajan, director of preventive cardiology at Massachusetts General Hospital, will discuss the limitations of contemporary guidelines in identifying patients at high risk of coronary artery disease and how PRS can help address this problem. Dr. George Busby, CSO & co-founder at Allelica, will discuss software available to enable PRS analysis implementation in-house at genetics laboratories and health systems and the best practices for clinical application.

Attendees will learn about:

  • The role of PRS in estimating risk for cardiovascular and other common diseases.
  • How PRS has been used to identify and rectify limitations in current risk assessments.
  • How PRS is currently being integrated into patient care at leading healthcare institutions.

Sponsored by

Allelica
Wed
Dec
08
10:00 AM
US Eastern

Sponsored by LGC, Biosearch Technologies

A Targeted, Medium-High Density, Multiplexed Genotyping Platform for Marker-Assisted Plant Breeding

Marker-assisted breeding – a technique by which trait selection is aided by linking the trait with an associated genetic marker – requires access to high-throughput, low-cost genotyping of a genome-wide sample of DNA polymorphisms. Next-generation sequencing (NGS) approaches are often more cost-effective for large-scale applications compared to SNP arrays.

During this webinar, Mitchell J. Feldmann, postdoctoral researcher at the University of California, Davis, will discuss how targeted, medium-high density, multiplexed genotyping platforms can avoid several shortcomings of both SNP arrays and NGS-based genotyping by sequencing for heterozygous, outbred cultivated strawberry.

Learn how a high-throughput, medium-high density genotyping platform populated with 5,000 sub-genome specific SNPs connected to the 50K FanaSNP Axiom array for cultivated strawberries was designed and tested. Markers were selected to best reproduce genomic relationship matrices calculated with the 50K FanaSNP array and to cover the linkage landscape in a large diversity panel of exotic, heirloom, and modern cultivars.

Attendees will learn about:

  • Marker-assisted breeding.
  • Platform development and testing.
  • The analyses enabled by a high level of connectivity across platforms.

Sponsored by

field_file_image_alt_text_value
Thu
Dec
09
12:00 PM
US Eastern

Sponsored by Qiagen

Latent Tuberculosis Infection Testing, Control, and Management in Diabetes Mellitus

Tuberculosis (TB) is a leading cause of morbidity and mortality due to an infectious agent, with nearly 10 million new cases and 1.4 million deaths worldwide in 2019. Type 2 diabetes is a risk factor for the development of active TB. The global increase in type 2 diabetes, with 642 million cases predicted worldwide by 2040, poses a challenge for TB control. The elderly are an understudied and vulnerable population with a high prevalence of diabetes and are highly susceptible to TB, with 20 to 30 percent dying from the disease.

In this webinar, Blanca I. Restrepo will describe the epidemiological landscape of TB and diabetes, with contrasting observations between adults and the elderly. Most notably, the elderly have a high prevalence of type 2 diabetes, yet this is not associated with higher odds of TB in this population. Also, Restrepo and colleagues find that elderly vaccinated with the BCG vaccine at birth appear to be more protected from developing TB. These provocative findings require further testing in other cohorts. Finally, Restrepo will discuss the challenges for latent TB infection testing in the elderly and the performance of the QuantiFERON-Gold Plus TB test.

Sponsored by

field_file_image_alt_text_value
Mon
Dec
13
2:00 PM
US Eastern

Sponsored by Illumina

Collaboratively Designed Genomic Tools to Maximize Both Genetic Gain and Economic Efficiency in Aquacultural Breeding Programs

Genomics can deliver great benefits to aquacultural breeding programs, including efficient management of diversity and inbreeding, accurate parentage assignment, optimal mating designs, improved breeding value prediction, selection decisions, and breeding strategies. Using the appropriate platform for the population of interest is critical. It is often expected that optimal results require a customized tool with a higher level of initial investment and larger ongoing costs. However, it is possible to keep costs reasonable with optimal outcomes through the creation or use of a collaboratively designed universal genotyping platform.

Collaborative genotyping solutions for specific species are created using diverse populations to ensure a design that contains a core set of markers with broad utility among all populations along with markers that capture specific population characteristics. The design also provides the ability to capture published markers associated with key traits. Many industry parties can benefit through using such platforms, creating a sample volume to keep costs reasonable and enabling results and outcomes that are easily compared and evaluated. As the platform is updated and improved, the benefit flows to all users. A successful example of this approach is in the livestock domain, where the widely used, collaboratively designed Illumina BovineSNP50 BeadChip array allows for high-throughput, cost-effective genetic screening for many genomic applications — including genomic selection — across both the dairy and beef industries. More recent extensions of this concept have been deployed as GeneSeek Genomic Profiler (GGPs) arrays. The updated content over time can leverage the continuously developing knowledge base about the genomic structure of a species as new tools and resources become available.

In this talk, Dr. Klara Verbyla, director of genomics and breeding and associate vice president of genetics at The Center for Aquaculture Technologies, will discuss the benefits of using such an approach for aquaculture species, as exemplified by the recent creation of a collaborative genotyping platform for L. vannamei shrimp designed using samples from 11 populations. Verbyla will discuss the design of the array, validating the array’s results, achieving maximal benefit from such an array, and the economic impacts of creating and using such genotyping platforms.

Sponsored by

field_file_image_alt_text_value
Tue
Dec
14
10:00 AM
US Eastern

Sponsored by Tecan

Epigenome-Wide Analysis of Multiple System Atrophy and Neurodegenerative Diseases From Brain Tissue

DNA methylation profiling is an important tool in understanding various diseases, including neurodegenerative diseases such as multiple systems atrophy (MSA). Research has shown that the 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) methylation states play different roles in gene expression, but traditional bisulfite conversion methods result in a single readout of total methylation level without differentiating 5mC and 5hmC.

In this webinar, Jörg Tost, director of the Laboratory for Epigenetics and Environment at the Centre National de Recherche en Genomique Humaine, will discuss a cost-effective and streamlined method of integrating Tecan’s TrueMethyl oxBS module upstream of methylation arrays such as Infinium MethylationEPIC. He will present results from studies utilizing this method on prefrontal cortex brain tissue to examine 5mC and 5hmC changes in MSA disease progression. He will also demonstrate the successful combination of the TrueMethyl oxBS module with amplicon sequencing to analyze regions identified through methylation arrays and whole genome oxidative bisulfite sequencing.

Attendees will:

  • Learn about the important roles of 5mC and 5hmC in the regulation of gene expression.
  • Understand the significance of differentiating between 5mC and 5hmC in epigenome-wide association analyses.
  • Become familiar with the methods of integrating Tecan’s TrueMethyl oxBS module with various downstream applications to analyze 5mC and 5hmC levels at single-nucleotide resolution.

Tecan genomics reagents are for Research Use Only. Not for diagnostic procedures.

Sponsored by

field_file_image_alt_text_value
Wed
Dec
15
1:00 PM
US Eastern

Sponsored by BioLegend

Single-Cell Multiomic Analysis of Thymocyte Development

CD4 and CD8 T cells play critical roles in the mammalian immune system. While their development within the thymus from the CD4+CD8+ stage has been widely studied as a model of lineage commitment, the underlying mechanism remains unclear.

In this webinar, Aaron Streets of UC Berkeley will discuss how this process can be deconstructed by applying CITE-seq to measure the transcriptome and over 100 surface proteins in thymocytes from wild-type and lineage-restricted mice. Streets will explain how totalVI can be used to jointly analyze the paired measurements to build a comprehensive timeline of RNA and protein expression in each lineage. This data supports a sequential model of lineage determination in which both lineages go through an initial phase of CD4 lineage audition, which is followed by divergence and specification of CD8 lineage cells.Participants can expect to learn:

  • How the totalVI computational pipeline can be used to interpret CITE-seq data.
  • How single-cell multiomic measurements can be integrated with traditional flow cytometry to generate a hypothesis.
  • A comprehensive model for T-cell development in the thymus.

Sponsored by

field_file_image_alt_text_value
Thu
Dec
16
3:00 PM
US Eastern

Sponsored by Invitae

Error Corrected Sequencing and Variant Calling Approaches to Characterize Evolution of Clonal Hematopoiesis

In this webinar, Kelly Bolton, assistant professor of oncology at Washington University, will discuss the development and validation of a custom next-generation sequencing panel that targets genes commonly mutated in clonal hematopoiesis. She will address the challenges, approaches, and pitfalls of variant calling in clonal hematopoiesis. Finally, Bolton will discuss the application of this panel to a study of how clonal hematopoiesis evolves under the selective pressure of different oncologic therapies, including PARPi therapy, in 500 solid tumor patients.

Sponsored by

Wed
Jan
12
1:00 PM
US Eastern

Sponsored by Tecan

Understanding the Role of the Microbiome in Deficient and Proficient Mismatch Repair Colorectal Cancers

Links between colorectal cancer (CRC) and the gut microbiome have been established, but the specific microbial species and their roles in carcinogenesis remain active areas of inquiry. Part of the mystery behind these links relates to the different methods of study that bias toward different signatures. In this webinar, Nicholas Chia will present work that elucidates the role of specific subtypes of CRC and discuss the implications of these findings for future research.

Chia and colleagues collected paired colon tumor and normal-adjacent tissue and mucosa samples from 83 individuals who underwent partial or total colectomies for CRC. Mismatch repair (MMR) status was determined in each tumor sample and classified as either deficient MMR (dMMR) or proficient MMR (pMMR) tumor subtypes. Samples underwent 16S rRNA gene sequencing and a subset of samples from 50 individuals were submitted for targeted metabolomic analysis to quantify amino acids and short-chain fatty acids. A PERMANOVA was used to identify the biological variables that explained variance within the microbial communities. dMMR and pMMR microbial communities were then analyzed separately using a generalized linear mixed-effects model that accounted for MMR status, sample location, intra-subject variability, and read depth.

Sponsored by

field_file_image_alt_text_value
Thu
Feb
03
12:00 PM
US Eastern

Sponsored by Beckman Coulter

Engineering the Immune Landscape with Synthetic Biology

Like any sufficiently understood system, human innate and adaptive immunity can be tweaked. As researchers move from understanding the components and interactions within these programs to manipulating them, engineering principles like iterative design and scalability are raising new possibilities to influence the biological determinants of health. Join us for a discussion among experts on how synthetic biology, driven by a new generation of lab tools, is helping scientists push towards new therapies and diagnostics.  

Sponsored by

field_file_image_alt_text_value